Literature DB >> 6211130

Neocarzinostatin in cancer chemotherapy (review).

H Maeda.   

Abstract

This article describes previous studies on a unique protein antitumor antibiotic, neocarzinostatin. Namely, its chemical nature, mode of action at molecular and cellular levels, toxicity and pharmacology, and recent results in clinical trials obtained primarily in Japan have been reviewed briefly.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6211130

Source DB:  PubMed          Journal:  Anticancer Res        ISSN： 0250-7005            Impact factor:   2.480


  10 in total

1.  Specific cytotoxic effect of neocarzinostatin conjugated to monoclonal antibody A7 on human pancreatic carcinoma.

Authors:  E Otsuji; T Takahashi; T Yamaguchi; N Yamaguchi; J Imanishi
Journal:  Gastroenterol Jpn       Date:  1990-04

2.  Selective toxicity of neocarzinostatin-monoclonal antibody conjugates to the antigen-bearing human melanoma cell line in vitro.

Authors:  G Lüders; W Köhnlein; C Sorg; J Brüggen
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

3.  Antitumor resistance induced by zinostatin stimalamer (ZSS), a polymer-conjugated neocarzinostatin (NCS) derivative. I. Meth A tumor eradication and tumor-neutralizing activity in mice pretreated with ZSS or NCS.

Authors:  E Masuda; H Maeda
Journal:  Cancer Immunol Immunother       Date:  1995-05       Impact factor: 6.968

Review 4.  Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting.

Authors:  Khaled Greish; Jun Fang; Takao Inutsuka; Akinori Nagamitsu; Hiroshi Maeda
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Stimulation of non-specific resistance to tumors in the mouse using a poly(maleic-acid-styrene)-conjugated neocarzinostatin.

Authors:  F Suzuki; R B Pollard; H Maeda
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  "Two-route chemotherapy" using high-dose intra-arterial neocarzinostatin and systemic tiopronin, its antidote, for rat limb tumor.

Authors:  Y Iwamoto; T Kuroiwa; K Aoki; T Baba
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication.

Authors:  C J Li; L J Zhang; B J Dezube; C S Crumpacker; A B Pardee
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 12.779

8.  Follow-up study of patients treated with monoclonal antibody-drug conjugate: report of 77 cases with colorectal cancer.

Authors:  T Takahashi; T Yamaguchi; K Kitamura; A Noguchi; M Honda; E Otsuji
Journal:  Jpn J Cancer Res       Date:  1993-09

9.  Efficacy of two-route chemotherapy using intraperitoneal neocarzinostatin and its antidote, intravenous tiopronin, for peritoneally disseminated tumors in mice.

Authors:  K Hasuda; H Kobayashi; T Kuroiwa; K Aoki; S Taniguchi; T Baba
Journal:  Jpn J Cancer Res       Date:  1989-03

10.  Differential neutralizing effect of tiopronin on the toxicity of neocarzinostatin and SMANCS: a new rescue cancer chemotherapy.

Authors:  T Oda; H Yamamoto; T Miki; H Maeda
Journal:  Jpn J Cancer Res       Date:  1989-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.